Last updated: November 18, 2024
Sponsor: Tor Biering-Sørensen
Overall Status: Active - Recruiting
Phase
4
Condition
Respiratory Syncytial Virus (Rsv)
Respiratory Syncytial Virus (Rsv) Infection
Treatment
RSV prefusion F protein-based vaccine
Clinical Study ID
NCT06684743
DAN-RSV
2024-516600-42-00
Ages > 60 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria
Age 60 years and above
Informed consent form has been signed and dated
Exclusion
Exclusion Criteria:
- There are no specific exclusion criteria for this study
Study Design
Total Participants: 130000
Treatment Group(s): 1
Primary Treatment: RSV prefusion F protein-based vaccine
Phase: 4
Study Start date:
November 18, 2024
Estimated Completion Date:
August 31, 2027
Study Description
Connect with a study center
Center for Translational Cardiology and Pragmatic Randomized Trials Department of Cardiology Copenhagen University Hospital - Herlev and Gentofte
Copenhagen, 2900
DenmarkSite Not Available
Danske Lægers Vaccinations Service
Søborg, 2860
DenmarkActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.